Skip to content
OpenCapital
Get started

Coherus BioSciences CHRS Q3 2025 earnings

Reported November 6, 2025 · After market close

Revenue$11.6MMiss by $2.5M
EPS-$0.33Miss by $0.01
Revenue estimate$14.1M
EPS estimate-$0.32

Next report

Aug 5, 2026 (In 1 week)
Revenue estimate$14.4M
EPS estimate-$0.12

Versus estimates

Revenue

Q1 2026$12.3MMiss by $1.9MQ4 2025$12.7MMiss by $1.2M
Q3 2025$11.6MMiss by $2.5M
Q2 2025$10.3MMiss by $1.7MQ1 2025$7.6MMiss by $53.4MQ4 2024$54.1MMiss by $5.9M

Diluted EPS

Q1 2026-$0.25Beat by $0.01Q4 2025-$0.34Beat by $0.02
Q3 2025-$0.33Miss by $0.01
Q2 2025-$0.34Miss by $0.03Q1 2025-$0.35Miss by $0.04Q4 2024-$0.28Miss by $0.18

Ask the moment Coherus BioSciences reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Coherus BioSciences report Q3 2025 earnings?
Coherus BioSciences (CHRS) reported Q3 2025 earnings on November 6, 2025 after market close.
What were Coherus BioSciences's Q3 2025 revenue and EPS?
Coherus BioSciences reported revenue of $11.6M and eps of $-0.33 for Q3 2025.
Did Coherus BioSciences beat estimates in Q3 2025?
Revenue missed the consensus estimate of $14.1M by $2.5M. EPS missed the consensus estimate of $-0.32 by $0.01.
How did Coherus BioSciences's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 83.7% from $70.8M a year earlier and eps declined 3200.0% from $-0.01.
Where can I find Coherus BioSciences's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001104659-25-107780) and the 10-Q periodic report (0001104659-25-107852) directly on SEC EDGAR. The filing index links above go to sec.gov.